Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; and a patent license agreement, and research and development agreement with the National Cancer Institute. The company was formerly known as ZIOPHARM Oncology, Inc. and changed its name to Alaunos Therapeutics, Inc. in January 2022. Alaunos Therapeutics, Inc. is headquartered in Houston, Texas.
Revenue of Alaunos Therapeutics, Inc. (TCRT)
Revenue in 2023 (TTM): $5 K
According to Alaunos Therapeutics, Inc.'s latest financial reports the company's current revenue (TTM) is $5 K. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of Alaunos Therapeutics, Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $5 K | $-4,798,000 | $-30,904,000 | $-35,140,000 | $-35,140,000 |
| 2022 | $2.92 M | $163 K | $-31,817,000 | $-37,730,000 | $-37,597,000 |
| 2021 | $398 K | $-342,000 | $-74,972,000 | $-78,751,000 | $-76,894,000 |
| 2020 | $ | $-1,128,000 | $-78,848,000 | $-79,976,000 | $-78,848,000 |
| 2019 | $ | $-629,000 | $-117,167,000 | $-117,796,000 | $-177,918,000 |
| 2018 | $146 K | $146 K | $-53,331,000 | $-53,117,000 | $-53,117,000 |
| 2017 | $6.39 M | $6.39 M | $-53,124,000 | $-54,323,000 | $-54,323,000 |
| 2016 | $6.86 M | $6.86 M | $-165,007,000 | $-165,297,000 | $-165,297,000 |
| 2015 | $4.33 M | $4.33 M | $-119,731,000 | $-120,088,000 | $-120,088,000 |
| 2014 | $1.37 M | $1.37 M | $-43,499,000 | $-31,781,000 | $-31,781,000 |
| 2013 | $800 K | $800 K | $-56,975,000 | $-57,107,000 | $-57,107,000 |
| 2012 | $800 K | $800 K | $-102,169,000 | $-96,132,000 | $-96,132,000 |
| 2011 | $667 K | $667 K | $-71,400,000 | $-63,778,000 | $-63,778,000 |
| 2010 | $ | $ | $-32,482,000 | $-32,670,000 | $-32,670,000 |
| 2009 | $ | $ | $-7,319,000 | $-7,649,000 | $-7,649,000 |
| 2008 | $ | $ | $-24,843,000 | $-25,231,000 | $-25,231,000 |
| 2007 | $ | $ | $-26,174,893 | $ | $-26,608,246 |
| 2006 | $ | $ | $-17,682,999 | $-17,856,919 | $-17,856,919 |
| 2005 | $ | $ | $-9,415,691 | $ | $-9,516,923 |
| 2004 | $ | $ | $-5,653,344 | $-39,166 | $-39,166 |
| 2003 | $ | $ | $-35,356 | $-35,842 | $-35,842 |
| 2002 | $2.57 K | $2.57 K | $-39,142 | $-39,941 | $-39,941 |
| 2001 | $1.73 K | $1.73 K | $-71,785 | $-72,535 | $-72,535 |